Brivaracetam for spinal cord injury-related neuropathic pain: results of a pilot double-blinded, randomized, placebo-controlled clinical trial.

Findings were similar but did not reach statistical significance when considering “worst pain” (−1.8 ± 1.5 vs −0.8 ± 1.2, P = 0.1), “least pain” (−0.2 ± 1.0 vs 0.5 ± 1.2, P = 0.3), “average pain” (−0.5 ± 1.9 vs −0.3 ± 0.7, P = 0.8), and composite pain (−0.8 ± 1.1 vs 0.1 ± 0.5, P = 0.1).

also in 111,027 other papers